Board approves preferential issue of shares and warrants worth Rs 58 crore

Fund Raising View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹374.00

prior close

₹380.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%+4.3% vs market

Pharmaceuticals peers, median of 173sector-0.7%+5.0% vs sector

On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+0.0+4.3-0.7+5.0

Next day

+5.4+1.3+4.1+0.6+4.8

+4.1+1.1+3.0+0.3+3.7

-0.7-1.7+1.0-2.3+1.6

-0.0-1.4+1.4-2.1+2.1

+1.9-0.6+2.5-2.5+4.4

+6.4+0.3+6.1-2.5+9.0

15d

+16.4-6.1+22.5-4.4+20.9

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved preferential issue of 12,22,200 equity shares at Rs 336.60 to non-promoters (Rs 41.14 crore) and up to 5,00,400 convertible warrants at Rs 336.60 to promoter and non-promoter groups (Rs 16.84 crore). Total potential raise about Rs 58 crore across 33 allottees. EGM on October 27, 2026. Promoter holding will reduce from 62.46 percent to 56.35 percent post-issue.

Likely market impact

Equity dilution of about 19 percent on fully diluted basis. Promoter stake drops 6 percentage points. Subject to shareholder approval at EGM.